<DOC>
	<DOCNO>NCT00175955</DOCNO>
	<brief_summary>An 8-week study examine safety efficacy levetiracetam patient neuroleptic-induced tardive dyskinesia</brief_summary>
	<brief_title>Levetiracetam Treatment Neuroleptic-induced Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Dyskinesia , Drug-Induced</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Subjects age 18 80 year Subjects must diagnosis stable axis I psychiatric disorder least 6 month prior screen Subjects must stable neurolepticinduced tardive dyskinesia least 1 month prior screen meet tardive dyskinesia severity criterion Subjects must use antipsychotic least 6 cumulative month , , stable dose 1 month prior screen Presence axis II condition within 6 month prior screen Huntington´s disease , idiopathic dystonia , Wilson´s disease , Sydenham´s chorea , thyroid dysfunction , spontaneous dyskinesia Start drugsother neuroleptic cause dyskinesia Presence additional major disease cardiac , renal hepatic dysfunction terminal illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Neuroleptic-induced tardive dyskinesia</keyword>
	<keyword>Keppra , Levetiracetam</keyword>
</DOC>